Contact, publication, and social network information about Harvard faculty and fellows. Harvard Catalyst Profiles
Keywords
Last Name
Institution

connectionKenneth David Mandl, M.D.

Co-Authors

This is a "connection" page, showing publications co-authored by Kenneth Mandl and Florence Bourgeois.

 
Connection Strength
 
 
 
10.921
 
  1. Mandl KD, Bourgeois FT. The Evolution of Patient Diagnosis: From Art to Digital Data-Driven Science. JAMA. 2017 Oct 26.
    View in: PubMed
    Score: 0.995
  2. Bourgeois FT, Olson KL, Tse T, Ioannidis JP, Mandl KD. Prevalence and Characteristics of Interventional Trials Conducted Exclusively in Elderly Persons: A Cross-Sectional Analysis of Registered Clinical Trials. PLoS One. 2016; 11(5):e0155948.
    View in: PubMed
    Score: 0.901
  3. Bourgeois FT, Olson KL, Poduri A, Mandl KD. Comparison of Drug Utilization Patterns in Observational Data: Antiepileptic Drugs in Pediatric Patients. Paediatr Drugs. 2015 Oct; 17(5):401-10.
    View in: PubMed
    Score: 0.862
  4. Bourgeois FT, Kim JM, Mandl KD. Premarket safety and efficacy studies for ADHD medications in children. PLoS One. 2014; 9(7):e102249.
    View in: PubMed
    Score: 0.792
  5. Bourgeois FT, Olson KL, Ioannidis JP, Mandl KD. Association between pediatric clinical trials and global burden of disease. Pediatrics. 2014 Jan; 133(1):78-87.
    View in: PubMed
    Score: 0.762
  6. Bourgeois FT, Murthy S, Pinto C, Olson KL, Ioannidis JP, Mandl KD. Pediatric versus adult drug trials for conditions with high pediatric disease burden. Pediatrics. 2012 Aug; 130(2):285-92.
    View in: PubMed
    Score: 0.691
  7. Bourgeois FT, Murthy S, Mandl KD. Comparative effectiveness research: an empirical study of trials registered in ClinicalTrials.gov. PLoS One. 2012; 7(1):e28820.
    View in: PubMed
    Score: 0.666
  8. Bourgeois FT, Shannon MW, Valim C, Mandl KD. Adverse drug events in the outpatient setting: an 11-year national analysis. Pharmacoepidemiol Drug Saf. 2010 Sep; 19(9):901-10.
    View in: PubMed
    Score: 0.606
  9. Bourgeois FT, Murthy S, Mandl KD. Outcome reporting among drug trials registered in ClinicalTrials.gov. Ann Intern Med. 2010 Aug 03; 153(3):158-66.
    View in: PubMed
    Score: 0.603
  10. Bourgeois FT, Valim C, McAdam AJ, Mandl KD. Relative impact of influenza and respiratory syncytial virus in young children. Pediatrics. 2009 Dec; 124(6):e1072-80.
    View in: PubMed
    Score: 0.575
  11. Bourgeois FT, Simons WW, Olson K, Brownstein JS, Mandl KD. Evaluation of influenza prevention in the workplace using a personally controlled health record: randomized controlled trial. J Med Internet Res. 2008 Mar 14; 10(1):e5.
    View in: PubMed
    Score: 0.511
  12. Bourgeois FT, Porter SC, Valim C, Jackson T, Cook EF, Mandl KD. The value of patient self-report for disease surveillance. J Am Med Inform Assoc. 2007 Nov-Dec; 14(6):765-71.
    View in: PubMed
    Score: 0.491
  13. Bourgeois FT, Valim C, Wei JC, McAdam AJ, Mandl KD. Influenza and other respiratory virus-related emergency department visits among young children. Pediatrics. 2006 Jul; 118(1):e1-8.
    View in: PubMed
    Score: 0.454
  14. Bourgeois FT, Olson KL, Brownstein JS, McAdam AJ, Mandl KD. Validation of syndromic surveillance for respiratory infections. Ann Emerg Med. 2006 Mar; 47(3):265.e1.
    View in: PubMed
    Score: 0.440
  15. Bourgeois FT, Orenstein L, Ballakur S, Mandl KD, Ioannidis JPA. Exclusion of Elderly People from Randomized Clinical Trials of Drugs for Ischemic Heart Disease. J Am Geriatr Soc. 2017 Nov; 65(11):2354-2361.
    View in: PubMed
    Score: 0.239
  16. Dunn AG, Zhou X, Hudgins J, Arachi D, Mandl KD, Coiera E, Bourgeois FT. Financial competing interests were associated with favorable conclusions and greater author productivity in nonsystematic reviews of neuraminidase inhibitors. J Clin Epidemiol. 2016 Dec; 80:43-49.
    View in: PubMed
    Score: 0.228
  17. Dunn AG, Coiera E, Mandl KD, Bourgeois FT. Conflict of interest disclosure in biomedical research: A review of current practices, biases, and the role of public registries in improving transparency. Res Integr Peer Rev. 2016; 1.
    View in: PubMed
    Score: 0.225
  18. Murthy S, Mandl KD, Bourgeois FT. Industry-sponsored clinical research outside high-income countries: an empirical analysis of registered clinical trials from 2006 to 2013. Health Res Policy Syst. 2015 Jun 05; 13:28.
    View in: PubMed
    Score: 0.211
  19. Dunn AG, Mandl KD, Coiera E, Bourgeois FT. The effects of industry sponsorship on comparator selection in trial registrations for neuropsychiatric conditions in children. PLoS One. 2013; 8(12):e84951.
    View in: PubMed
    Score: 0.191
  20. Murthy S, Mandl KD, Bourgeois F. Analysis of pediatric clinical drug trials for neuropsychiatric conditions. Pediatrics. 2013 Jun; 131(6):1125-31.
    View in: PubMed
    Score: 0.182
  21. Bourgeois FT, Mandl KD, Valim C, Shannon MW. Pediatric adverse drug events in the outpatient setting: an 11-year national analysis. Pediatrics. 2009 Oct; 124(4):e744-50.
    View in: PubMed
    Score: 0.142
  22. Kimia A, Brownstein JS, Olson KL, Zak V, Bourgeois FT, Mandl KD. Lumbar puncture ordering and results in the pediatric population: a promising data source for surveillance systems. Acad Emerg Med. 2006 Jul; 13(7):767-73.
    View in: PubMed
    Score: 0.112
  23. Dunn AG, Bourgeois FT, Murthy S, Mandl KD, Day RO, Coiera E. The role and impact of research agendas on the comparative-effectiveness research among antihyperlipidemics. Clin Pharmacol Ther. 2012 Apr; 91(4):685-91.
    View in: PubMed
    Score: 0.042
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.